A citation-based method for searching scientific literature

Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Li Mao, Giovanni Selvaggi, Xiaobin Yuan, Yuanqing Fu, Tao Wang, Shanshan Xiao, Li Zhang. Lancet Respir Med 2020
Times Cited: 64



D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis, Byoung Chul Cho, Li Zhang, Denis Moro-Sibilot, Ting Liu, Walter Bordogna, Bogdana Balas, Barbara Müller, Alice T Shaw. J Thorac Oncol 2019
Times Cited: 209




List of shared articles



Times cited

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.
Yunpeng Yang, Jie Huang, Tao Wang, Jianya Zhou, Jing Zheng, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong,[...]. J Thorac Oncol 2021
12

Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Ling Peng, Liping Zhu, Yilan Sun, Justin Stebbing, Giovanni Selvaggi, Yongchang Zhang, Zhentao Yu. Front Oncol 2022
3

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li,[...]. Signal Transduct Target Ther 2022
1

Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Alice Indini, Erika Rijavec, Michele Ghidini, Claudia Bareggi, Donatella Gambini, Barbara Galassi, Paola Antonelli, Giulia Bettio, Clarissa Di Nubila, Francesco Grossi. Expert Opin Pharmacother 2020
6

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Diego Kauffmann-Guerrero, Kathrin Kahnert, Rudolf M Huber. Drugs 2021
6

First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
Yuxiang Ma, Hongyun Zhao, Jinhui Xue, Li Liu, Nong Yang, Yang Zhang, Haiyan Yang, Shaodong Hong, Yi Xiong, Zhonghan Zhang,[...]. Eur J Cancer 2022
0

The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor.
Xinru Chen, Xiangchan Hong, Gang Chen, Jinhui Xue, Jie Huang, Fan Wang, Wael Ab Dullah Sultan Ali, Jing Li, Li Zhang. Transl Oncol 2022
5

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
6

Non-small cell lung cancer in China.
Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou. Cancer Commun (Lond) 2022
1

Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy.
Giuseppe Bronte, Alessandro Cafaro, Luigi Pasini, Ilaria Priano, Kalliopi Andrikou, Paola Cravero, Marco Angelo Burgio, Angelo Delmonte, Lucio Crinò. Expert Rev Anticancer Ther 2021
2

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Liling Huang, Shiyu Jiang, Yuankai Shi. J Hematol Oncol 2020
82

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer.
Cheng-Hao Chuang, Hsiao-Ling Chen, Hsiu-Mei Chang, Yu-Chen Tsai, Kuan-Li Wu, I-Hua Chen, Kung-Chao Chen, Jui-Ying Lee, Yong-Chieh Chang, Chin-Ling Chen,[...]. Cancers (Basel) 2021
16



ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
Jun Jiang, Cong Zhao, Fang Zhang, Zhenhua Liu, Kaiyuan Zhou, Xinling Ren, Yi Wan. BMJ Open 2022
0

The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.
Yue Pan, Chao Deng, Zhenhua Qiu, Chenghui Cao, Fang Wu. Front Oncol 2021
12

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer.
Valerio Gristina, Maria La Mantia, Federica Iacono, Antonio Galvano, Antonio Russo, Viviana Bazan. Pharmaceuticals (Basel) 2020
29